KZR Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-04-27 | 2022 | John Fowler Chief Executive Officer | 575,000 | 0 | 0 | 332,063 | 12,848 | 6,193,511 |
| 2023-04-27 | 2021 | Noreen Roth Henig, M.D. Chief Medical Officer | 475,000 | 0 | 0 | 218,500 | 12,032 | 1,811,616 |
| 2023-04-27 | 2022 | Noreen Roth Henig, M.D. Chief Medical Officer | 500,000 | 0 | 0 | 210,000 | 12,848 | 2,621,344 |
| 2023-04-27 | 2021 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 443,000 | 0 | 0 | 203,780 | 12,032 | 1,685,890 |
| 2023-04-27 | 2022 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 468,000 | 0 | 0 | 196,560 | 12,848 | 2,470,432 |
| 2023-04-27 | 2021 | John Fowler Chief Executive Officer | 567,000 | 0 | 0 | 326,025 | 12,032 | 5,645,417 |
| 2022-04-26 | 2021 | Noreen Roth Henig, M.D. Chief Medical Officer | 475,000 | 0 | 0 | 218,500 | 12,032 | 1,811,616 |
| 2022-04-26 | 2021 | John Fowler Chief Executive Officer | 567,000 | 0 | 0 | 326,025 | 12,032 | 5,645,417 |
| 2022-04-26 | 2020 | John Fowler Chief Executive Officer | 546,000 | 0 | 0 | 243,789 | 11,994 | 1,265,683 |
| 2022-04-26 | 2021 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 443,000 | 0 | 0 | 203,780 | 12,032 | 1,685,890 |
| 2022-04-26 | 2020 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 426,000 | 0 | 0 | 152,167 | 11,994 | 880,099 |
| 2022-04-26 | 2020 | Noreen Roth Henig, M.D. Chief Medical Officer | 286,667 | 0 | 0 | 174,477 | 11,697 | 1,459,001 |
| 2021-04-29 | 2020 | John Fowler Chief Executive Officer | 546,000 | 0 | 0 | 243,789 | 11,994 | 1,265,683 |
| 2021-04-29 | 2019 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 410,000 | 0 | 0 | 114,800 | 11,794 | 1,942,334 |
| 2021-04-29 | 2019 | John Fowler Chief Executive Officer | 525,000 | 0 | 0 | 183,750 | 11,794 | 3,532,024 |
| 2021-04-29 | 2020 | Noreen Roth Henig, M.D. ( 4 ) | 286,667 | 0 | 0 | 174,477 | 11,697 | 1,459,001 |
| 2021-04-29 | 2020 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 426,000 | 0 | 0 | 152,167 | 11,994 | 880,099 |
| 2020-04-29 | 2019 | Niti Goel, M.D. Former Chief Medical Officer | 309,053 | 0 | 0 | 0 | 614,237 | 2,128,210 |
| 2020-04-29 | 2018 | Niti Goel, M.D. Former Chief Medical Officer | 266,250 | 15,000 | 0 | 86,265 | 11,431 | 1,201,310 |
| 2020-04-29 | 2019 | Marc Belsky | 375,000 | 0 | 0 | 105,000 | 11,794 | 1,595,872 |
| 2020-04-29 | 2019 | John Fowler Chief Executive Officer | 525,000 | 0 | 0 | 183,750 | 11,794 | 3,532,024 |
| 2020-04-29 | 2018 | John Fowler Chief Executive Officer | 460,000 | 0 | 0 | 248,400 | 11,601 | 1,800,543 |
| 2020-04-29 | 2019 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 410,000 | 0 | 0 | 114,800 | 11,794 | 1,942,334 |
| 2020-04-29 | 2018 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 365,000 | 0 | 0 | 137,970 | 11,601 | 962,353 |
| 2019-04-30 | 2018 | Niti Goel, M.D. (4 ) | 266,250 | 15,000 | 0 | 86,265 | 11,431 | 1,201,310 |
| 2019-04-30 | 2017 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 325,000 | 0 | 0 | 111,000 | 10,800 | 745,276 |
| 2019-04-30 | 2017 | John Fowler Chief Executive Officer | 360,000 | 0 | 0 | 130,000 | 10,800 | 799,276 |
| 2019-04-30 | 2018 | John Fowler Chief Executive Officer | 460,000 | 0 | 0 | 248,400 | 11,601 | 1,800,543 |
| 2019-04-30 | 2018 | Christopher Kirk, Ph.D. President and Chief Scientific Officer | 365,000 | 0 | 0 | 137,970 | 11,601 | 962,353 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
